Colchis

Quick links to important sections

Colchis

Method of action: Antigout, Anti-Inflammatory

Treatment option: Gout, Fits, Behcet Syndrome

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Colchis

Property Description
Active ingredient Colchicine
Form Tablet / Film-coated tablet (Oral preparation)
Pharmacological class Anti-gout agent, Microtubule inhibitor
General purpose Suppression of specific acute inflammatory processes
Origin Natural origin (Alkaloid from Colchicum autumnale)

Colchis: Definition and Pharmacological Class

Colchis is a prescription-only medicine containing the active ingredient Colchicine, which is an anti-gout agent and a microtubule inhibitor. It is supplied as an oral preparation, typically a tablet or film-coated tablet. The role of Colchicine in managing specific inflammatory responses is established within its pharmacological profile.

This medicine’s core component, Colchicine, is a unique tricyclic alkaloid derived from a natural origin—specifically the seeds or corms of the autumn crocus (Colchicum autumnale). In terms of chemical nomenclature, Colchicine is a tropolone derivative. Its potent classification means it occupies a distinct role within medicine compared to common non-steroidal anti-inflammatory drugs.

Composition and Pharmaceutical Form

The Colchis preparation is a single-ingredient product, containing only Colchicine alongside the necessary solid oral vehicle or excipients required to form the tablet structure. The film-coated tablet form is a distinguishing feature, designed to aid in ingestion and ensure stability of the compound. Other marketed formulations containing Colchicine include brands such as Colcrys and Mitigare.

General Purpose of Colchicine

The general therapeutic purpose of Colchicine is to achieve a reduced inflammatory response by specifically targeting cellular processes. A typical neutral use scenario for the action of this medicine involves suppressing acute inflammatory episodes in affected joints.

The medication achieves this by acting as an inhibitor of tubulin polymerization, which restricts the physical recruitment and migration of inflammatory white blood cells (leukocytes) to sites of acute immune activity. By hindering this localized cellular movement, Colchicine delivers the general benefit of suppressing specific acute inflammatory processes characterized by cellular recruitment.

What side effects are possible with Colchis?

Possible Side Effects and Safety Information

The safety profile of Colchis (Colchicine) is officially organized by government regulatory bodies based on the frequency and the body system affected. Understanding these classifications is key to appreciating the medicine's risk profile, which is characterized by a high incidence of common, generally reversible effects, alongside the documentation of serious, less common adverse reactions.


Official Adverse Reactions and Systems

Adverse reactions are classified according to the following systems in official regulatory documents:

  • Most Common: Reactions involving the Gastrointestinal System, including diarrhea, nausea, vomiting, and abdominal pain. These symptoms are often cited as the first indicators of potential Colchicine toxicity.
  • Other Systems: Effects documented in other systems include disorders of the Blood and Lymphatic System (e.g., myelosuppression, leukopenia), Musculoskeletal System (e.g., myopathy, muscle weakness, rhabdomyolysis), and Nervous System (e.g., peripheral neuropathy).

Serious Safety Considerations

The prescribing information highlights several serious and potentially life-threatening risks:

  • Blood Dyscrasias: The occurrence of severe blood disorders such as aplastic anemia and pancytopenia has been documented, which may occur even with standard therapeutic use.
  • Neuromuscular Toxicity: Myopathy and rhabdomyolysis (severe muscle breakdown) are reported, particularly associated with chronic (long-term) treatment.
  • Fatal Overdose: Both accidental and intentional fatal overdose has been reported, underscoring the medicine's narrow therapeutic window.

Population-Specific Safety Notes

The risk profile is significantly altered for certain groups. Use of Colchicine is contraindicated when co-administered with strong inhibitors of CYP3A4 or P-gp transport proteins in patients who have renal (kidney) or hepatic (liver) impairment, due to the risk of life-threatening toxicity. Additionally, older adults are noted to be at an increased risk of neuromuscular toxicity, even with otherwise normal organ function.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Colchis (Colchicine) overdose emphasizes the potential for severe, delayed toxicity and the mandatory requirement for immediate medical attention. The initial presentation, typically within the first 24 hours of ingestion, involves severe gastrointestinal effects, including nausea, vomiting, abdominal pain, and profuse diarrhea, which can lead to significant fluid loss and hypotension.

Life-Threatening Manifestations and Action Required

Overdose progresses to a second, often fatal, stage that occurs between 24 and 72 hours, involving severe systemic complications. These documented life-threatening outcomes include progressive multi-organ failure, cardiac arrhythmias, and delayed bone marrow suppression (e.g., leukopenia, thrombocytopenia). Fatal cases have been reported even with relatively low doses.

Action Mandated by Regulators Description
Immediate Medical Attention All suspected overdose cases, including those that are initially asymptomatic, must be referred for immediate medical assessment and hospital monitoring .
Antidote Availability No specific antidote is known for Colchicine toxicity.
Supportive Treatment Treatment is primarily symptomatic and supportive, focused on maintaining fluid and electrolyte balance and managing shock.

Patients with renal impairment or hepatic impairment are identified in official labeling as being at a significantly increased risk of severe toxicity.

Therapeutic Uses of Colchis

What Colchis Treats: Main Uses and Benefits

Colchis (Colchicine) plays a role in managing symptoms related to inflammatory or irritative states across several primary clinical presentations. The medication is commonly used to help manage symptoms associated with gouty arthritis, Familial Mediterranean Fever (FMF), and conditions involving inflammatory or irritative states related to the cardiovascular system. It is utilized in situations involving certain distressing symptoms across these therapeutic areas.

In clinical settings that involve acute symptom patterns, Colchis is relevant for easing symptom clusters that may become intense or disruptive, such as sudden joint pain and swelling. Through its supportive role, it assists with maintaining functional stability and is commonly used to prevent these episodes from recurring. For chronic conditions like FMF, its long-term use supports patients during episodes of heightened discomfort, and contributes to the management of symptoms related to systemic imbalance.

“This medication is relevant for easing challenging symptoms associated with acute inflammation and plays a role in managing conditions characterized by periods of heightened physiological stress.”

The medication is also applied in clinical settings involving acute or unstable symptom patterns related to pericardial disease and is considered relevant for managing symptoms associated with acute or episodic changes in patients with established heart conditions. This supportive role is relevant for managing symptoms that interfere with daily comfort.


Quick Fact: Symptom Management Focus: Acute Joint Pain and Systemic Recurrence

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Colchis (colchicine) is used to treat and prevent conditions like gout flares and Familial Mediterranean Fever (FMF). Most adults can take it, but a healthcare provider must determine if it is safe for you based on your medical history.


Contraindications and Cautions

Colchis is contraindicated (should not be used) in patients with severe kidney or liver disease, as the drug can accumulate to toxic levels. It is also generally contraindicated in patients with pre-existing blood disorders (blood dyscrasias) and those with an allergic reaction to colchicine. Due to the risk of serious side effects, Colchis is also contraindicated in patients with kidney or liver impairment who are simultaneously taking certain medications that inhibit a drug-transporting protein called P-glycoprotein or an enzyme called CYP3A4. These interacting medications include certain antibiotics (e.g., clarithromycin), antivirals (e.g., for HIV), and some cholesterol-lowering drugs (e.g., simvastatin).


Special Populations

Condition Use of Colchis
Pregnancy Use only if the potential benefit outweighs the risk to the fetus.
Breastfeeding Use with caution; the infant should be monitored for side effects like diarrhea.
Elderly Patients Dosing may need adjustment due to a higher risk of toxicity from age-related changes in kidney or liver function.

Avoid consuming grapefruit or grapefruit juice while taking Colchis, as this can increase drug levels in the body and heighten the risk of serious side effects.

What should I know about interactions with other medicines?

The official interaction profile for Colchis (Colchicine) is governed primarily by its handling by two critical clearance pathways: the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter. Co-administration with medicinal products that inhibit both of these pathways significantly interferes with Colchicine clearance, leading to dangerously increased systemic exposure. Due to the high risk of life-threatening toxicity from this effect, regulatory documents state that the combination with dual strong CYP3A4/P-gp inhibitors is formally contraindicated in patients who have pre-existing renal impairment or hepatic impairment.

For patients with normal organ function, if co-administration with a P-gp inhibitor or strong CYP3A4 inhibitor is required, the official regulatory guidance mandates a reduction in Colchicine dosage or temporary interruption of treatment.

Separately, a pharmacodynamic interaction exists with agents that affect muscle tissue. An increased risk of myopathy (muscle disease) and rhabdomyolysis is officially documented when Colchicine is combined with drugs known to cause these effects, notably HMG-CoA Reductase Inhibitors (Statins) and Fibrates.

Regarding substances, official labeling explicitly restricts the co-administration of grapefruit juice, as it is known to increase Colchicine plasma concentrations.

Mechanism of Action

How Colchis Works: A Mechanistic Overview

Colchicine (Colchis) functions by engaging molecular mechanisms central to the acute and chronic inflammatory response, focusing on disrupting cellular structural integrity and subsequent signaling, resulting in the attenuation of inflammatory responses.

Disruption of Microtubule Dynamics and Cell Motility

This core mechanistic domain involves colchicine’s high-affinity binding to the protein tubulin, thereby inhibiting the assembly of microtubules. The resulting collapse of the cellular cytoskeleton significantly impairs essential cell functions, particularly the chemotaxis and motility of neutrophils, which are innate immune cells. This physical impediment decreases the accumulation and infiltration of inflammatory cells.

Inhibition of NLRP3 Inflammasome Activation

Colchicine modulates a key upstream signaling mechanism by interfering with the activation of the NLRP3 inflammasome. This multi-protein complex is critical for recognizing cellular danger and initiating inflammatory cascades. By stabilizing the cellular components required for the inflammasome's proper assembly, the drug effectively suppresses the processing and secretion of highly pro-inflammatory cytokines, primarily Interleukin-1beta (IL-1beta). This effect contributes to the reduction of systemic inflammatory signaling.

Regulation of Downstream Inflammatory Mediators

The drug’s structural and signaling-level interventions lead to cascade effects on downstream physiological outcomes. By reducing neutrophil activity and suppressing IL-1beta release, colchicine limits the generation of other inflammatory signals, such as certain chemokines and leukotrienes. This mechanistic adjustment contributes to the modulation of physiological responses within tissues.

Dosage and Administration Information

The administration of Colchis (Colchicine) follows established protocols which define the route, dose, frequency, and duration for its use. The medicine is primarily available as an oral preparation, typically tablets or capsules, and is intended to be swallowed whole, generally without regard to meals.

Official Administration Patterns

Use Scenario Initial Dosing Regimen Frequency and Constraint
Acute Gout Flare 1.2 mg dose followed by 0.6 mg one hour later. Total 1.8 mg course; subsequent courses restricted to at least 3 days (72 hours) later.
Gout Prophylaxis 0.6 mg once or twice daily. The maximum recommended intake must not exceed 1.2 mg per day.
FMF (Maintenance) 1.2 mg to 2.4 mg daily. Total daily dose may be given in one or two divided doses.

Dosing Adjustments and Context

Dose modifications are utilized for specific patient populations. For example, for patients with severe renal impairment, the acute gout flare course is limited to a single 0.6 mg dose, and maintenance regimens require a lower starting dose. Pediatric dosing for Familial Mediterranean Fever (FMF) starts at a low daily amount and is titrated based on age and body mass. Patients on a prophylaxis regimen must wait 12 hours after an acute treatment dose before resuming their regular maintenance schedule. The instruction map for Colchicine establishes a structured protocol that strictly limits the total dose and frequency.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Colchis (Colchicine)

Evidence for Use in Gouty Arthritis

Colchicine was studied in research exploring short-term changes related to acute gout flares, which are conditions characterized by fluctuating or episodic manifestations of intense pain and swelling. Researchers utilized short-term Randomized Controlled Trials (RCTs) to compare different ways of using the medicine against a placebo or against other anti-inflammatory approaches in adults experiencing increased symptom activity.

The studies focused on measuring outcomes related to physical discomfort, such as pain intensity on standardized scales, objective joint swelling, and the time until measured outcomes changed. Research also examined the medicine was evaluated in studies observing responses in patients who were beginning other long-term gout treatments, focusing on the frequency of recurrent flares.

Evidence for Use in Familial Mediterranean Fever (FMF)

For Familial Mediterranean Fever (FMF), which is a condition involving periods of heightened symptoms and functional imbalance, the research base includes both RCTs and substantial long-term prospective observational studies. These studies typically included both adults and pediatric patients with FMF.

Long-term observational research monitored outcomes related to systemic imbalance, specifically tracking the development of conditions such as amyloidosis. Long-term cohort studies described patterns where the frequency of acute FMF attacks changed over the study period when compared to observed populations not using the medicine. These findings are documented in both pediatric and adult populations.

Evidence for Use in Pericardial Diseases

Colchicine was evaluated in multiple, dedicated, large-scale Randomized Controlled Trials (RCTs) for conditions associated with acute or disruptive episodes, specifically acute and recurrent pericarditis. These trials used a double-blind, placebo-controlled design where the medicine was observed in patients receiving standard anti-inflammatory therapy.

Research primarily examined outcomes describing episodic or acute changes, focusing on the primary endpoints of the rate of recurrent pericarditis episodes, the time to the first recurrence, and the proportion of patients reporting a specific measured change in symptoms.

Key Studies & References

  1. Colchicine DMB 0.5 mg and 1 mg, tablets (colchicine) - Summary of Product Characteristics (SmPC) (EMA-related document)

Frequently Asked Questions (FAQ)

Common questions about Colchis (FAQ)

Q: Is there a generic version of Colchis available?

A: The active ingredient in Colchis is colchicine, which is available as a generic medication. Official sources confirm that generic versions exist alongside brand-name products.

Q: Do you need regular blood tests while you are taking Colchis?

A: Official product information indicates that regular monitoring of complete blood counts, liver function, and kidney function tests is generally recommended. This monitoring is advised to track for potential serious side effects, such as blood disorders or issues with organ function, as described in regulatory documentation.

Q: Can Colchis interact with common over-the-counter pain relievers?

A: Official documents do not list specific interactions with all common over-the-counter pain relievers. However, since the risk of interactions exists with many medications, consultation with a healthcare professional regarding all combined products is advised.

Q: Does Colchis interact with supplements like vitamins or herbal products?

A: Some herbal products and nutritional supplements are known to interfere with the body's natural clearance processes for Colchis, such as the CYP3A4 enzyme and P-glycoprotein transporter. If these processes are inhibited, it could lead to dangerously increased levels of the medicine. The complete list of all supplements should be reviewed with the prescribing healthcare provider due to this risk.

Q: Is there a list of specific foods to avoid while on Colchis?

A: According to official regulatory documents, the only food substance explicitly restricted is grapefruit and its juice. Consuming grapefruit may interfere with how the body handles the medicine and could increase the risk of serious side effects. Colchis is otherwise generally taken without regard to meals.

Q: What is the definition of a 'contraindication' for Colchis?

A: A contraindication is a clear reason why a medicine must not be used because the risks of harm are far too high. For Colchis, this includes pre-existing severe organ problems or using specific types of other medicines that interfere with how Colchis is cleared from the body.

Q: What should be done if someone accidentally takes too much Colchis?

A: Official warnings state that fatal overdose has been reported with Colchis, highlighting its narrow margin for safety. If an accidental overdose is suspected, official guidance strongly advises seeking emergency medical care immediately.

Q: How quickly does Colchis start working for a gout attack?

A: Studies conducted for acute gout flares have examined how quickly the medicine begins to work. Clinical trial evidence indicates that a significant reduction in pain was observed within 24 hours of initiating the treatment course, compared to placebo.

Q: Why do official documents warn about using Colchis with certain heart medicines?

A: Official warnings are targeted at medications that interfere with the body's natural clearance systems for Colchis, specifically the CYP3A4 enzyme and P-glycoprotein transporter. Because certain heart medications (like some calcium channel blockers) can block these systems, taking them with Colchis can cause dangerously high levels of Colchis in the body and increase the risk of toxicity.

Q: Can Colchis be split in half if the pill is large?

A: Official drug information states that the tablets are scored and can be split in half. This is based on regulatory standards for dosage forms.

Q: Are there any official reports of Colchis causing hair loss?

A: Official regulatory documents list hair loss, or alopecia, as a reported adverse reaction. This is based on post-marketing experience and is included in the dermatological category of potential side effects.

Q: What is the maximum duration Colchis has been studied for long-term use?

A: The duration of long-term use, such as for the prevention of gout flares, is determined by a patient’s specific condition. Official clinical guidelines often recommend continuation for a period of 3 to 6 months or potentially longer, as required for a prophylaxis plan.

Q: Is it true that Colchis was used historically for other purposes?

A: Studies and historical records indicate that the active ingredient in Colchis has been used for centuries. For example, historical records mention its use dating back to ancient times for the alleviation of pain and swelling.

Q: Is Colchis addictive?

A: Regulatory documents state that there have been no reports of abuse, dependence, or tolerance related to the use of colchicine.

Q: Is there a risk of developing a tolerance to Colchis over time?

A: Official product information reports that there has been no documentation of tolerance developing to colchicine over time. The concepts of abuse or dependence have also not been reported.

Q: Does alcohol change how Colchis works in the body?

A: Alcohol consumption is not listed as directly interfering with the way the medicine works in the body. However, official guidance points out that alcohol can increase uric acid levels, which may worsen the underlying gout condition.

Q: Is Colchis considered a first-line treatment for gout?

A: Clinical guidance, supported by evidence, generally considers Colchis to be an effective option for the treatment of acute gout flares. Specifically, the low-dose regimen is widely advised as a first-line approach when initiated early in an acute episode.

Q: Can taking Colchis make you tired or dizzy?

A: While not always listed as common adverse reactions, fatigue and dizziness are potential symptoms. Official documents indicate they can be associated with signs of possible colchicine toxicity or overdose and are monitored as safety signals.

Q: Is it normal for a doctor to prescribe Colchis together with allopurinol?

A: It is a documented and established practice for Colchis to be prescribed alongside other medications like allopurinol. This combination is commonly used to help prevent gout flares when beginning a long-term uric acid-lowering treatment.

Q: Does Colchis come in different strengths?

A: According to official product labeling, the standard commercially available tablet strength is 0.6 mg.

Q: Can Colchis affect cholesterol levels?

A: Studies have investigated the effects of Colchis beyond inflammation, noting that it may influence the formation and expansion of cholesterol crystals. This research suggests a potential benefit in cardiovascular conditions separate from its primary anti-inflammatory actions.

Q: Are the side effects of Colchis dose-dependent?

A: Official prescribing information indicates that the incidence of the most common gastrointestinal side effects, such as nausea, vomiting, and diarrhea, is reported to be dose-related.

Q: Does Colchis affect fertility in men or women?

A: Official information contains warnings for males of reproductive potential. Regulatory labeling advises that the medicine may, in rare cases, transiently impair fertility, an effect that appears to be reversible once treatment is stopped.

Q: What is the purpose of the black box warning on Colchis (if any)?

A: The FDA issued a major safety communication, similar in function to a Black Box Warning, to highlight a severe risk. This warning addresses the potential for fatal toxicity when Colchis is taken with strong inhibitors of the CYP3A4 enzyme or P-glycoprotein transporter in patients who also have kidney or liver impairment.

How should Colchis be stored and disposed of?

How to Store and Dispose of Colchicine

Official regulatory documents define strict conditions for the storage and disposal of Colchicine (Colchis) to ensure product stability and safety.

Storage Environment and Container Rules

The medication must be stored at Controlled Room Temperature, specifically between 20^circ and 25 C (68^circ to 77 F). The container must be kept tightly closed and requires a light-resistant quality to protect the tablets or capsules from both light and moisture. The storage environment should avoid temperature extremes outside the permitted range.

Child-Safety and Disposal

All Colchicine products must be kept out of the reach of children due to the high risk of toxicity. Regarding disposal, unused or expired medication must be discarded according to local regulations or via authorized pharmaceutical take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colchis found in:

A-Z Index: